KR20080066663A - 맞춤화된 항암 화학요법（ｐａｃ）을 위한 종합적인 진단테스트 방법 - Google Patents

맞춤화된 항암 화학요법（ｐａｃ）을 위한 종합적인 진단테스트 방법 Download PDF

Info

Publication number
KR20080066663A
KR20080066663A KR1020087006823A KR20087006823A KR20080066663A KR 20080066663 A KR20080066663 A KR 20080066663A KR 1020087006823 A KR1020087006823 A KR 1020087006823A KR 20087006823 A KR20087006823 A KR 20087006823A KR 20080066663 A KR20080066663 A KR 20080066663A
Authority
KR
South Korea
Prior art keywords
cancer
tumor
drug
drug response
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020087006823A
Other languages
English (en)
Korean (ko)
Inventor
폴 오.피. 츠'오
스티븐 레스코
Original Assignee
씨씨씨 디아그노스틱스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨씨씨 디아그노스틱스 엘엘씨 filed Critical 씨씨씨 디아그노스틱스 엘엘씨
Publication of KR20080066663A publication Critical patent/KR20080066663A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020087006823A 2005-09-21 2006-09-21 맞춤화된 항암 화학요법（ｐａｃ）을 위한 종합적인 진단테스트 방법 Withdrawn KR20080066663A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71872405P 2005-09-21 2005-09-21
US60/718,724 2005-09-21
US77890106P 2006-03-06 2006-03-06
US60/778,901 2006-03-06

Publications (1)

Publication Number Publication Date
KR20080066663A true KR20080066663A (ko) 2008-07-16

Family

ID=37889517

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087006823A Withdrawn KR20080066663A (ko) 2005-09-21 2006-09-21 맞춤화된 항암 화학요법（ｐａｃ）을 위한 종합적인 진단테스트 방법

Country Status (6)

Country Link
US (1) US20070071762A1 (https=)
EP (1) EP1946114A4 (https=)
JP (2) JP2009509171A (https=)
KR (1) KR20080066663A (https=)
CA (1) CA2623445A1 (https=)
WO (1) WO2007035842A2 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2359689B1 (en) * 2002-09-27 2015-08-26 The General Hospital Corporation Microfluidic device for cell separation and use thereof
US8921102B2 (en) * 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
EP2029779A4 (en) 2006-06-14 2010-01-20 Living Microsystems Inc HIGHLY PARALLEL SNP GENOTYPING UTILIZATION FOR FETAL DIAGNOSIS
US20080090239A1 (en) * 2006-06-14 2008-04-17 Daniel Shoemaker Rare cell analysis using sample splitting and dna tags
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
EP2235536A4 (en) * 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2-DIAGNOSTIC PROCEDURE
SG192544A1 (en) * 2008-01-31 2013-08-30 Univ Keio Marker for determination of sensitivity to anti-cancer agent
WO2010028288A2 (en) 2008-09-05 2010-03-11 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
CA3069082C (en) 2008-09-20 2022-03-22 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
DE102009047146B4 (de) 2009-11-25 2012-07-19 Ulrich Pachmann Verfahren zum Vorhersagen des Ansprechens einer Tumorerkrankung auf eine therapeutische Maßnahme
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
JP5951603B2 (ja) 2010-07-07 2016-07-13 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ 乳がんの診断および治療
EP2619329B1 (en) 2010-09-24 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
JP5900489B2 (ja) * 2011-03-25 2016-04-06 コニカミノルタ株式会社 免疫組織染色法、およびこれを用いた抗体医薬の有効性を判定する方法
EP2726870B1 (en) 2011-06-29 2018-10-03 Academia Sinica The capture, purification and release of biological substance using a surface coating
CN102409087B (zh) * 2011-08-11 2014-01-01 厦门艾德生物医药科技有限公司 一种用于测定β-微管蛋白III 基因表达的引物、探针及检测试剂盒
KR101327533B1 (ko) 2012-12-11 2013-11-08 사회복지법인 삼성생명공익재단 환자 맞춤형 항암제 선별용 시스템
WO2014194289A1 (en) * 2013-05-31 2014-12-04 Nektar Therapeutics Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents
TW201623605A (zh) 2014-04-01 2016-07-01 中央研究院 用於癌症診斷及預後之方法及系統
US10112198B2 (en) 2014-08-26 2018-10-30 Academia Sinica Collector architecture layout design
US10746740B2 (en) 2015-01-22 2020-08-18 Konica Minolta, Inc. Biological substance quantitation method, pathological diagnosis support system, and recording medium storing computer readable program
US12106213B2 (en) 2016-02-01 2024-10-01 Mitchell International, Inc. Systems and methods for automatically determining adjacent panel dependencies during damage appraisal
US12190358B2 (en) 2016-02-01 2025-01-07 Mitchell International, Inc. Systems and methods for automatically determining associations between damaged parts and repair estimate information during damage appraisal
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
WO2019191280A1 (en) * 2018-03-27 2019-10-03 Laboratory Corporation Of America Holdings Sandwich elisa for identifying subjects who may benefit from treatment with therapeutic agents
CN112082976A (zh) * 2019-06-14 2020-12-15 天津方得生物科技有限公司 基于药物探针及组织切片的体外药物敏感性检测方法
CN111458514A (zh) * 2019-12-18 2020-07-28 王�琦 一种外周血中的肿瘤细胞株数量的检测方法
CN111458515A (zh) * 2019-12-18 2020-07-28 王�琦 一种外周血中的肺小细胞肿瘤细胞数量的检测方法
JP7806660B2 (ja) * 2022-11-11 2026-01-27 コニカミノルタ株式会社 検出方法
PL444462A1 (pl) * 2023-04-18 2024-10-21 Uniwersytet Medyczny W Białymstoku Sposób oceny chemiowrażliwości komórek nowotworowych in vitro na leki przeciwnowotworowe i sposób diagnostyki ex vivo nowotworu piersi

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU744095B2 (en) * 1997-03-27 2002-02-14 Baker Norton Pharmaceuticals, Inc. Methods and compositions for treatment of ovarian cancer
EP1283904A2 (en) * 1999-11-03 2003-02-19 Oncotech, Inc. Cancer diagnosis using cell-sorting and gene-expression-profiles
EP1286671B1 (en) * 2000-05-15 2006-04-05 Celgene Corporation Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan
DE10043591A1 (de) * 2000-09-01 2002-03-14 Max Delbrueck Centrum Verfahren zur Erfassung von Resistenz-Profilen von Geweben und Zellinien
ES2374311T3 (es) * 2002-03-13 2012-02-15 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados.
US20030190689A1 (en) * 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
ES2542328T3 (es) * 2002-12-06 2015-08-04 Millennium Pharmaceuticals, Inc. Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma
WO2004052184A2 (en) * 2002-12-12 2004-06-24 Oncotech, Inc. Genes related to sensitivity and resistance to chemotherapeutic drug treatment
EP1649052A1 (en) * 2003-08-01 2006-04-26 The University Of Western Australia Methods and kits for predicting the likelihood of successful treatment of cancer
EP1697751A2 (en) * 2003-12-04 2006-09-06 Ludwig Institute For Cancer Research Assay and treatment
WO2006055676A2 (en) * 2004-11-16 2006-05-26 The Uab Research Foundation Molecular basis for the identification of chemotherapy resistance in human tumors and the treatment thereof

Also Published As

Publication number Publication date
CA2623445A1 (en) 2007-03-29
EP1946114A2 (en) 2008-07-23
US20070071762A1 (en) 2007-03-29
EP1946114A4 (en) 2010-05-26
WO2007035842A3 (en) 2007-09-20
WO2007035842A2 (en) 2007-03-29
JP2009509171A (ja) 2009-03-05
JP2012177706A (ja) 2012-09-13

Similar Documents

Publication Publication Date Title
KR20080066663A (ko) 맞춤화된 항암 화학요법（ｐａｃ）을 위한 종합적인 진단테스트 방법
Koh et al. Heterogeneous expression of programmed death receptor-ligand 1 on circulating tumor cells in patients with lung cancer
Arnould et al. Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH)
JP6259828B2 (ja) 未分化リンパ腫キナーゼ（ａｌｋ）をマーカーとして使用する治療応答性非小細胞肺癌の同定法
Nitta et al. New methods for ALK status diagnosis in non–small-Cell lung Cancer: an improved ALK immunohistochemical assay and a new, Brightfield, dual ALK IHC–In situ hybridization assay
WO2003016867A2 (en) Method and quantification assay for determining c-kit/scf/pakt status
JP2015527055A (ja) 細胞全体でのアッセイおよび方法
Asioli et al. Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer
Abe et al. Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non–small-cell lung carcinomas: A comparative study between small biopsy and excision samples
WO2009102729A1 (en) Association of biomarkers with patient outcome
WO2004077021A2 (en) Standardized evaluation of therapeutic efficacy based on cellular biomarkers
Matsushita et al. Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer
KR20050111752A (ko) 항신생물제에 의한 치료에 대한 종양의 감수성을 결정하는방법
Zhu et al. Six stroma-based RNA markers diagnostic for prostate cancer in European-Americans validated at the RNA and protein levels in patients in China
Zhou et al. The diagnostic and clinical significance of TFE3 immunohistochemical nuclear expression in solitary fibrous tumour
US8557527B2 (en) Correlation of molecular markers with clinical outcome in GBM patients radiation treated with or without gefitinib
EP2710379A1 (en) Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
Wilkinson et al. Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibition
EP1946112A2 (en) Predictive methods for cancer chemotherapy
Słodkowska et al. Digital pathology in personalized cancer therapy
JP2024514506A (ja) テリソツズマブベドチンを使用した非小細胞肺がんの治療方法
RU2846787C1 (ru) Способ выявления циркулирующих клеток в крови больных раком легкого с помощью проточной цитометрии с использованием опухолеспецифичных ДНК-аптамеров
Słodkowska et al. Digital pathology in personalized cancer therapy
Ulvang et al. Co-expression of tissue factor, TROP2, and NECTIN4 in primary and matched metastatic cervical cancer lesions
HK1123095A (en) Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy (pac)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D12-X000 Request for substantive examination rejected

St.27 status event code: A-1-2-D10-D12-exm-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000